乳腺癌是女性最常见的恶性肿瘤之一,其发病率逐年上升的趋势,并且.docVIP

·论著· 人乳腺癌原代培养体外药敏试验研究 100021 北京 中国医学科学院肿瘤医院肿瘤所生物检测中心 李艳芬，田海梅，陈国际2，曹冬艳，刘毅，李茉，王小兵，刘朝阳，梁智，程冬婉，张伟1 [摘要]目的: 探讨用ATP生物荧光肿瘤体外药敏检测技术（ATP-TCA）研究乳腺癌药敏的异质性和个体化疗的可行性。 方法: 用ATP-TCA检测114例乳腺癌标本对13种单药或联合用药的敏感性。结果: 个体之间的药物敏感性存在着明显的异质性。单药中最有效的药物为紫杉醇、长春瑞滨、表阿霉素、丝裂霉素和阿霉素，分别有73.3％、64.1％、62.3％、49.9％和40.0％的标本对其敏感。联合用药（紫杉醇＋表阿霉素，环磷酰胺＋表阿霉素＋氟尿嘧啶）的敏感率高于单药。结论：乳腺癌对抗癌药物的敏感程度存在着异质性。ATP生物荧光肿瘤药敏检测技术可用于为乳腺癌选择合适的化疗药物。 [关键词] ATP生物荧光肿瘤药敏检测技术；乳腺癌；化疗药物敏感性 中图分类号：R737.9 文献标识码：A 文章编号：1009-0460(2006)00-0000-00 Evaluation of chemosensitivity of human breast cancer determined by primary culture assay in vitro LI Yan-fen, TIAN Hai-mei, CHEN Guo-ji, CAO Dong-yan, LIU Yi, LI Mo, WANG Xiao-bing, LIU Zhao-yang, LIANG Zhi, CHENG Dong-wan, ZHANG Wei. Tumor Marker Research Center, Cancer Hospital/Institute, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing 100021, China Corresponding auther: ZHANG Wei, E-mail: zhangww1954@126.com [Abstract] Objective To investigate the heterogeneity of chemosensitivity in breast cancer using an ATP-tumor chemosensitivity assay (ATP-TCA) and the feasibility of individual chemotherapy. Methods An ATP-TCA was used to determine the effect of 13 single or combined cytotoxic drugs in surgical specimens from 114 patients with breast cancer cancer. Results There were considerable differences in chemosensitivity between individuals. The most active single drug in the assay was identified as Paclitaxel, Navelbine, Epirubicin, Mitomycin and adriamycin, 73.3%, 64.1%, 62.3%, 49.9% and 40.0% of specimens showed sensitivity to them, respectively. Combination of chemotherapy (Paclitaxel+Epirubicin, Cyclophosphamide+Epirubicin+5-Fluorouracil) was found to be more effective than relative drugs alone. Conclusions There was the heterogeneity of the in vitro chemosensitivity in breast cancer. The use of the ATP-TCA provide a method of selecting appropriate anti-cancer drugs in breast cancer. [Key words] ATP-tumor chemosensitivity assay; Breast cancer; Chemosensitivity